Updates in the diagnosis, risk stratification & treatment of AML: WHO, ICC, and ELN classifications

#HEMEPATH Navigating Change and Integrating WHO 5th/ ICC Classification Systems in the diagnosis …Подробнее

Updates in the diagnosis, risk stratification & treatment of AML: WHO, ICC, and ELN classificationsПодробнее

AML risk stratificationПодробнее

Updates to the ICC classification of AMLПодробнее

Higher-risk MDS and AML: How new guidelines are changing diagnosis, classification and managementПодробнее

The impact of cytogenetic-risk stratification on AML outcomesПодробнее

Innovations in HematologyПодробнее

The impact of the 5th WHO classification and ICC of AML on diagnosis and treatment of HR AMLПодробнее

Validation of 2022 diagnostic & prognostic classifications of AMLПодробнее

Comparing the ICC and WHO classifications for secondary AML and their impact on clinical practiceПодробнее

The classification of AML and the role of genetic biomarkers in the management of AMLПодробнее

Updates on the use of molecular monitoring to detect MRD in AMLПодробнее

Know AML | Risk stratificationПодробнее

High-risk AML: the 2022 ELN risk classification and challenges in this patient populationПодробнее

European LeukemiaNet 2017 AML recommendations: impact on risk stratification and survivalПодробнее

Role of CPX-351 in Acute Myeloid LeukemiaПодробнее

Predicting the outcomes of patients with AML treated with CPX-351 based on ELN risk stratificationПодробнее

Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC): - J. F. Zeidner - 20221116Подробнее

Revisions to the ICC and WHO classifications of AML and MDSПодробнее

AML diagnosis and treatment 2022Подробнее